

Anti-BCA-225

Catalog No.	Description
AM968-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
AM968-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive™ Detection Systems and i6000™ Automated Staining Systems
MU968-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
MU968-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
AX968-YCD	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite Staining System, 160 tests
AX968-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite Staining System, 50 tests
AX968-4M	Ready-to-Use Antibody in Barcode labeled vial for use on the NanoVIP® Staining System, 50 tests

Clone	Species	Ig Class
BCA-225/C23	Mouse	IgG1/K

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of human BCA-225 in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

BCA-225 Breast carcinoma associated glycoprotein 225, or BCA-225, has been identified exclusively in breast cancers and certain adenocarcinomas, as one of the biomarkers. Unlike other identified proteins, monoclonal antibodies for BCA-225 (clones-CU18, CU26, and CU46) show no cross reactivity with lactating mammary glands and with gastrointestinal malignancies. This restricted distribution and frequency in breast carcinomas gives BCA-225 considerable clinical significance in diagnosis and treatment of breast and other adenocarcinomas.

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Principles of the Procedure

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The [primary antibody](#) may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Mouse Monoclonal Antibody to human BCA-225 is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations
Control Tissue	Breast cancer tissue as available with Biogenex FB-968M* & FG-968M*
Recommended Dilution for Concentrated Antibody	1:40-80 in HK941-YAK
Recommended Pretreatment (Manual/i6000)**	EZ-AR1 (HK521-XAK)
Recommended Pretreatment (Xmatrx & Nano VIP)	EZ-AR1 Elegance (HX031-YCD & HX046-08XN)
Antibody Incubation (Manual/i6000)	30-60 Min at RT
Antibody Incubation (Xmatrx & Nano VIP)	30-60 Min at 25°C
Detection System for Manual, Xmatrx, Nano VIP & i6000 systems***	Use BioGenex Two-Step OR One-Step Super Sensitive™ Polymer-HRP IHC Detection System/DAB; see p. 2 for more information

*FB: positive control micro chamber slides, FG: positive control non-barrier slides. Xmatrx & Nano VIP requires micro chamber slides.

**Pretreatment times will vary based on individual microwave power.

Category	Antibodies	Revision No.	F
Document No.	932-968M-EN	Release Date	17-Jun-2024

***For automation systems (Xmatrix-Elite, Nano VIP & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Detection System	Two-Step HRP Kit	One-Step HRP Kit	Link and Label Kit
Manual	QD440-XAKEN (1000 Test)	QD630-XAKEN (1000 Test)	QP300-XAKE (1000 Test)
	QD430-XAKEN (1000 Test)		
	QD420-YIKEN (500 Test)	QD620-XAKEN (500 Test)	QP900-9LE (500 Test)
	QD400-60KEN (60 Test)		
Xmatrix - Automation	QD550-YCDEN (200 Test)	QD610-YADEN (200 Test)	N/A
NanoVIP- Automation	QD551-YCDEN (100 Test)	QD611-YADEN (100 Test)	N/A
i6000 - Automation	QD410-YAXEN (200 Test)	QD610-YAXEN (200 Test)	N/A
For more information, visit www.biogenex.com .			

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report unusual staining.

Expected Results

This antibody stains cytoplasm in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user.

Experimental results should be confirmed by a medically-established diagnostic product or procedure.

Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

- Mesa Tejada R, et al. Immunocytochemical distribution of a breast carcinoma associated glycoprotein identified by monoclonal antibodies. Am J Pathol. 1988 Feb; 130(2):305-14.
- Loy TS, et al. Distribution of BCA-225 in adenocarcinomas. An immunohistochemical study of 446 cases. Am J Clin Pathol. 1991 Sep; 96(3):326-9.
- Ma CK, et al. Comparative immunohistochemical study of primary and metastatic carcinomas of the liver. Am J Clin Pathol. 1993 May; 99(5):551-7.
- Zombori T, Cserni G. Immunohistochemical Analysis of the Expression of Breast Markers in Basal-like Breast Carcinomas Defined as Triple Negative Cancers Expressing Keratin 5. Pathol Oncol Res. 2018 Apr; 24(2):259-267.
- Ri G, et al. Serum levels of CA15-3, KL-6 and BCA225 are positively correlated with each other in the general population. Anticancer Res. 2009 Oct; 29(10):4239-42.

	Temperature Limitation		In Vitro Diagnostic Medical Device
	Use By Date		Batch Code
	Non-Sterile		Consult Instructions for Use
	Representative in the European Community		Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	F
Document No.	932-968M-EN	Release Date	17-Jun-2024